Latest Orasure Technologies (OSUR) Headlines Up
Post# of 55
Posted On: 03/13/2014 12:12:14 PM
Latest Orasure Technologies (OSUR) Headlines
Uptrend Call Working As OraSure Technologies Stock Rises 19.2% (OSUR)
Comtex SmarTrend(R) - 1 hr 6 mins ago
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 3 weeks, OraSure Technologies has returned 19.23% as of today's recent price of $8.03.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
Why OraSure Technologies, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:07PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of OraSure Technologies , a marketer of...
OraSure Technologies to Present at the Cowen & Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34 Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
OraSure Technologies to Present at the Raymond James 35th Annual Institutional Investors Conference
GlobeNewswire - Mon Feb 24, 5:12AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 35 Annual Institutional Investors Conference in Orlando, Florida. The conference will be simultaneously webcast over the Internet.
Fusion Antibodies Announces Collaboration with Pepscan to offer Precision Epitope Mapping
PRWeb - Mon Feb 24, 2:08AM CST
UK based contract research organisation Fusion Antibodies and Dutch based biotechnology company Pepscan, a leading provider of epitope mapping services, have today announced a partnership to offer Pepscan's Precision Epitope Mapping platform to Fusion Antibodies clients. The partnership will have great benefits for Fusion Antibodies clients as it will offer them an integrated end-to-end solution for the pre-clinical development of antibodies. Fusion Antibodies can now not only provide Antibody Engineering, Humanization and development of high yielding stable cell lines but a range of high quality characterisation studies through their expert partners.
OraSure Technologies to Present at the 2014 Citi Global Healthcare Conference
GlobeNewswire - Thu Feb 20, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2014 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
OraSure Technologies (OSUR) Jumps: Stock Up 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:51AM CST
OraSure Technologies, Inc. was a big mover last session, as its shares rose over 10% on the day.
Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Why OraSure Technologies, Inc. Shares Popped
Alex Planes, The Motley Fool - Motley Fool - Thu Feb 06, 12:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of OraSure Technologies, have gained 10%...
OraSure Technologies to Present at the Leerink Swan Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald Spair, Chief Operating Officer & Chief Financial Officer, will speak to the investment community at the Leerink Swan Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
OraSure Announces Record Full-Year and Quarterly Revenues
GlobeNewswire - Wed Feb 05, 3:00PM CST
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2013.
OraSure Technologies Announces 2014 Annual Meeting Date
GlobeNewswire - Tue Jan 28, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2014 Annual Meeting of Stockholders is scheduled to be held on Thursday, May 22, 2014. Further details regarding the meeting will be provided at a later date.
Janssen Announces New Group Targeting Unmet Global Health Needs
PR Newswire - Wed Jan 22, 7:15AM CST
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs. Janssen GPH will align the company's groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Mon Jan 20, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2013 fourth quarter and full year financial results and certain 2014 financial guidance for 5:00 pm ET (2:00 pm PT) Wednesday, February 5, 2014. An update on certain business developments will also be provided.
10 Countries With the Shortest Life Expectancy
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 10:16AM CST
Yesterday, we examined the envy of the rest of the world: 10 countries with the longest life expectancy . Today, we're going to flip the table and examine the other point of view: 10 countries with the shortest life expectancy. As the World Health...
2013 Report on the In-Vitro Diagnostic Substance Manufacturing Industry Features Players such as Hologic, Inc. and Quidel Corporation
M2 - Tue Jan 07, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dvwjc/invitro) has announced the addition of Supplier Relations US, LLC's new report "In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. The industry's revenue for the year 2012 was reported at $12.6 billion USD, with an estimated gross profit of 43.66%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $19.6 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. This 2013 year-end publication of In-Vitro Diagnostic Substance Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. At 173 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. This current report contains shipment data, inventory levels, international trade volume, and industry specific price indices available through September 2013. Industry analysts and Fortune 500 customers rely on this quarterly report to make accurate forecasts and planning in today's uncertain economy. Companies Mentioned: - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/7dvwjc/invitro Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OraSure Technologies Addresses FDA Warning Letter Received by Its Subsidiary DNA Genotek
GlobeNewswire - Tue Jan 07, 8:52AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) announced that its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the U.S. Food and Drug Administration (FDA) which the FDA posted today on its website. The warning letter primarily focuses on DNA Genotek's response to two observations issued by the FDA on Form 483 as a result of a routine inspection of DNA Genotek's Ottawa, Canada facilities in September 2013.
Uptrend Call Working As OraSure Technologies Stock Rises 19.2% (OSUR)
Comtex SmarTrend(R) - 1 hr 6 mins ago
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 18th, 2014 at $6.74. In approximately 3 weeks, OraSure Technologies has returned 19.23% as of today's recent price of $8.03.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Ways You Can Be a Better Health-Care Investor Than Warren Buffett
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 09, 1:03PM CDT
Behind only three other people on this planet -- Bill Gates, Carlos Slim, and Amancio Ortega -- stands Warren Buffett with $58.2 billion in accumulated wealth, according to Forbes ' latest rankings of the world's richest people. Buffett, perhaps...
Why OraSure Technologies, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:07PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of OraSure Technologies , a marketer of...
OraSure Technologies to Present at the Cowen & Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Cowen & Co. 34 Annual Health Care Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
OraSure Technologies to Present at the Raymond James 35th Annual Institutional Investors Conference
GlobeNewswire - Mon Feb 24, 5:12AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 35 Annual Institutional Investors Conference in Orlando, Florida. The conference will be simultaneously webcast over the Internet.
Fusion Antibodies Announces Collaboration with Pepscan to offer Precision Epitope Mapping
PRWeb - Mon Feb 24, 2:08AM CST
UK based contract research organisation Fusion Antibodies and Dutch based biotechnology company Pepscan, a leading provider of epitope mapping services, have today announced a partnership to offer Pepscan's Precision Epitope Mapping platform to Fusion Antibodies clients. The partnership will have great benefits for Fusion Antibodies clients as it will offer them an integrated end-to-end solution for the pre-clinical development of antibodies. Fusion Antibodies can now not only provide Antibody Engineering, Humanization and development of high yielding stable cell lines but a range of high quality characterisation studies through their expert partners.
OraSure Technologies to Present at the 2014 Citi Global Healthcare Conference
GlobeNewswire - Thu Feb 20, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the 2014 Citi Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
OraSure Technologies (OSUR) Jumps: Stock Up 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:51AM CST
OraSure Technologies, Inc. was a big mover last session, as its shares rose over 10% on the day.
Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Why OraSure Technologies, Inc. Shares Popped
Alex Planes, The Motley Fool - Motley Fool - Thu Feb 06, 12:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of OraSure Technologies, have gained 10%...
OraSure Technologies to Present at the Leerink Swan Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald Spair, Chief Operating Officer & Chief Financial Officer, will speak to the investment community at the Leerink Swan Global Healthcare Conference in New York City. The conference will be simultaneously webcast over the Internet.
OraSure Announces Record Full-Year and Quarterly Revenues
GlobeNewswire - Wed Feb 05, 3:00PM CST
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter of 2013.
OraSure Technologies Announces 2014 Annual Meeting Date
GlobeNewswire - Tue Jan 28, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that its 2014 Annual Meeting of Stockholders is scheduled to be held on Thursday, May 22, 2014. Further details regarding the meeting will be provided at a later date.
Janssen Announces New Group Targeting Unmet Global Health Needs
PR Newswire - Wed Jan 22, 7:15AM CST
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs. Janssen GPH will align the company's groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Mon Jan 20, 5:00AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2013 fourth quarter and full year financial results and certain 2014 financial guidance for 5:00 pm ET (2:00 pm PT) Wednesday, February 5, 2014. An update on certain business developments will also be provided.
10 Countries With the Shortest Life Expectancy
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 10:16AM CST
Yesterday, we examined the envy of the rest of the world: 10 countries with the longest life expectancy . Today, we're going to flip the table and examine the other point of view: 10 countries with the shortest life expectancy. As the World Health...
2013 Report on the In-Vitro Diagnostic Substance Manufacturing Industry Features Players such as Hologic, Inc. and Quidel Corporation
M2 - Tue Jan 07, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dvwjc/invitro) has announced the addition of Supplier Relations US, LLC's new report "In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. The industry's revenue for the year 2012 was reported at $12.6 billion USD, with an estimated gross profit of 43.66%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $19.6 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. This 2013 year-end publication of In-Vitro Diagnostic Substance Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. At 173 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. This current report contains shipment data, inventory levels, international trade volume, and industry specific price indices available through September 2013. Industry analysts and Fortune 500 customers rely on this quarterly report to make accurate forecasts and planning in today's uncertain economy. Companies Mentioned: - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/7dvwjc/invitro Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OraSure Technologies Addresses FDA Warning Letter Received by Its Subsidiary DNA Genotek
GlobeNewswire - Tue Jan 07, 8:52AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) announced that its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the U.S. Food and Drug Administration (FDA) which the FDA posted today on its website. The warning letter primarily focuses on DNA Genotek's response to two observations issued by the FDA on Form 483 as a result of a routine inspection of DNA Genotek's Ottawa, Canada facilities in September 2013.
(0)
(0)OraSure Technologies Inc. (OSUR) Stock Research Links
Scroll down for more posts ▼